COMPENSATION AND BENEFITS 15 15.1.2 SUMMARY TABLE OF COMPENSATION, financial year (ex post vo)te . Our shareholders’ meeting held on OPTIONS AND SHARES GRANTED TO SENIOR April 12,2018, in its 9thand 10 resolutions, voted accordinglyth EXECUTIVES FOR THE FISCAL YEARS 2016 AND 2017 on the elements of remuneration granted to Michael Wyzga and Fol lowing the entry into force of the Sapin 2 Law (French law Bernard Gilly during the financial year 2017, that are described no. 2016-1691 of December 9, 2016), the payment of the elements in the report of the Board of Directors include in the notice of of variable remuneration and, as appropriate, exceptional General Meeting. remuneration attributed for a financial year to Chairman of the The tables below constitute the information given accordingly Board, the Chief Executive Officer and of the Deputy CEOs is to the article L. 225-37-3 of the French Commercial Code and conditional on approval by the next ordinary general meeting of comply with AMF recommendation 2014-14. their elements of remuneration, paid or attributed during the said Table 1 (AMF definition) Fiscal year ending Fiscal year ending (in euros) December 31, 2016 December 31, 2017 Michael Wyzga Chairman Compensation due for the fiscal year 193,982 145,154 (as detailed in Section 15.1.3 of this Registration Document Valuation of multi-year variable compensation granted in the course — — of the fiscal year Valuation of share warrants granted during the fiscal year 91,140 24,600 (as detailed in Section 15.3.2 of this Registration Document) Valuation of share warrants for founders granted during the fiscal year — — (as detailed in Section 15.3.2 of this Registration Document) Valuation of shares warrants granted during the fiscal year — — (as detailed in Section 15.3.2 of this Registration Document) TOTAL 285,122 169,154 Fiscal year ending Fiscal year ending (in euros) December 31, 2016 December 31, 2017 Bernard Gilly Chief Executive Officer Compensation due for the fiscal year 416,280 534,018 (as detailed in Section 15.1.3 of this Registration Document Valuation of multi-year variable compensation granted in the course — — of the fiscal year Valuation of share warrants granted during the fiscal year — — (as detailed in Section 15.3.2 of this Registration Document) Valuation of share warrants for founders granted during the fiscal year — — (as detailed in Section 15.3.2 of this Registration Document) Valuation of free shares granted during the fiscal year 2,000,000 1,024,000 (as detailed in Section 15.3.2 of this Registration Document) TOTAL 2,416,280 1,558,018 156– GENSIGHT BIOLOGICS – 2017 Registration Document